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Background
Cancer cells undergoing necrosis or apoptosis release
fragmented, low-molecular weight DNA into the circula-
tion, which may be recovered from plasma and processed
for molecular analysis. This minimally invasive approach
represents a useful alternative to tumor biopsy and a
potential application in therapeutic interventions is the
periodic monitoring of circulating cell-free tumor DNA
for the identification of molecular changes associated
with resistance to target-specific treatments or when the
mutational status of tumor tissue is not available.
Scientific objectives
The present study screened KRAS mutant alleles in cell-
free circulating tumor DNA in a small cohort of patients
resistant to cetuximab treatment to investigate the
potential occurrence of KRAS-mutated cell clones aris-
ing in tumors as a consequence of selective pressure
exerted by cetuximab on KRAS wild-type cancer.
Technological approaches
Three patients were judged to have a KRAS wild-type pri-
mary tumor by standard molecular analysis. These patients
received standard chemotherapy with cetuximab and
eventually progressed on treatment. At the time of radi-
ologic evidence of disease progression they were screened
for the developent of KRAS somatic mutations as a
mechanism of secondary resistance. Peripheral blood sam-
ples (6 ml) were drawn at pre-cetuximab time-point (base-
line) and at PD during cetuximab administration. DNA
was extracted from plasma with QIAamp Circulating
Nucleic Acid Kit to recover DNA fragments of ≤1000 bp.
PCR amplification was carried out with a QX100™
ddPCR™ System (Bio-Rad) on 20 μL-samples containing
cftDNA and TaqMan probes for KRAS G12D (35G>A)
and G12V (35G>T) labeled with FAM/VIC. Samples were
then loaded into a droplet reader, which discriminates the
difference in fluorescence amplitudes on the basis of target
gene amplification.
Results interpretation
Analysis of the cell-free tumor DNA samples at PD in
patient 1 and 2 showed the presence of the KRAS muta-
tion G12V while in patient 3 the G12D mutation was
detected. Interestingly, pre-cetuximab cell-free tumor
DNA was positive for KRAS mutant alleles for patients
2 and 3, but was not sufficient to test the mutational
status of KRAS in patient 1.
Outlook and expert recommendations
ddPCR is a third-generation PCR technique for highly
sensitive detection of DNA mutations, which has impor-
tant application in the monitoring of patients for the
occurrence of secondary mutations that render their
tumors resistant to target-specific anticancer agents.
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